{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:24:35Z","timestamp":1793042675304,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.ygyno.2003.12.043","type":"journal-article","created":{"date-parts":[[2004,2,24]],"date-time":"2004-02-24T10:15:49Z","timestamp":1077617749000},"page":"131-136","source":"Crossref","is-referenced-by-count":40,"title":["The predictive and prognostic value of serum CA 125 half-life during paclitaxel\/platinum-based chemotherapy in patients with advanced ovarian carcinoma"],"prefix":"10.1016","volume":"93","author":[{"given":"Angiolo","family":"Gadducci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fanucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Negri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renza","family":"Cristofani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Riccardo","family":"Genazzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2003.12.043_BIB1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.humrep.a136832","article-title":"The CA 125 tumour-associated antigen: a review of the literature","volume":"4","author":"Jacobs","year":"1989","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0090-8258(88)90244-2","article-title":"Ovarian cancer: the prognostic value of the serum half-life of CA 125 during induction chemotherapy","volume":"30","author":"van der Burg","year":"1988","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/00016349009013306","article-title":"Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma","volume":"69","author":"Hogberg","year":"1990","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0090-8258(92)90082-T","article-title":"Serum CA 125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival","volume":"47","author":"Buller","year":"1992","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/gyno.1995.1181","article-title":"Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study","volume":"58","author":"Gadducci","year":"1995","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB6","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/sj.bjc.6690744","article-title":"CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer","volume":"81","author":"Peters-Engl","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2003.12.043_BIB7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB9","first-page":"356","article-title":"Cisplatin\/paclitaxel vs. carboplatin\/paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Study Group trial","volume":"18","author":"du Bois","year":"1999","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB10","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 7","key":"10.1016\/j.ygyno.2003.12.043_BIB11","first-page":"3","article-title":"Paclitaxel (Taxol)\/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer","volume":"27","author":"Ozols","year":"2000","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB13","first-page":"379","article-title":"Randomised trial of paclitaxel (PTX) and carboplatin (CBDCA) versus a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin): the third International Collaborative Ovarian Neoplasm Study (ICON 3)","volume":"19","author":"Colombo","year":"2000","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1040-8428(99)00036-0","article-title":"Up date in the management of advanced ovarian carcinoma","volume":"32","author":"Conte","year":"1999","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0959-8049(99)00210-5","article-title":"A new standard of care for treatment of ovarian cancer","volume":"36","author":"Piccart","year":"2000","journal-title":"Eur. J. Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2003.12.043_BIB16","first-page":"S2-34","article-title":"Taxane\/platinum\/anthracycline combination therapy in advanced epithelial ovarian cancer","volume":"24","author":"Hill","year":"1997","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1200\/JCO.1999.17.1.46","article-title":"First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I\/II study of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group","volume":"17","author":"du Bois","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0090-8258(03)00128-8","article-title":"First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients","volume":"89","author":"Romanini","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/(SICI)1097-0142(19960701)78:1<118::AID-CNCR17>3.0.CO;2-2","article-title":"CA 125: a valid marker in ovarian carcinoma patients treated with paclitaxel?","volume":"78","author":"Davelaar","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2003.12.043_BIB20","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1006\/gyno.1999.5699","article-title":"Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients","volume":"76","author":"Paulsen","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.1999.17.2.501","article-title":"Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel","volume":"17","author":"Bridgewater","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1046\/j.1525-1438.2002.01133.x","article-title":"The CA 125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer","volume":"12","author":"Tsuda","year":"2002","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2003.12.043_BIB23","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/0959-8049(92)90248-Z","article-title":"Modulation of tumour marker CA-125 expression in cultured ovarian carcinoma cells","volume":"28A","author":"Marth","year":"1992","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2003.12.043_BIB24","first-page":"3818","article-title":"Paclitaxel- and docetaxel-dependent activation of CA 125 expression in human ovarian carcinoma cells","volume":"57","author":"Marth","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000218036","article-title":"Effect of paclitaxel (Taxol) on CA 125 expression and release by ovarian cancer cell lines","volume":"18","author":"Bonfrer","year":"1997","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ygyno.2003.12.043_BIB26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/0002-9378(91)90093-7","article-title":"CA 125 regression: a model for epithelial ovarian cancer response","volume":"165","author":"Buller","year":"1991","journal-title":"Am. J. Obstet. Gynecol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825803009478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825803009478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:52:56Z","timestamp":1550191976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825803009478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0090825803009478"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2003.12.043","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}